Comparison of DR. HPV Chip Kit with hybrid capture II assay for the detection of human papillomavirus in clinical samples: a preliminary study.
Human papillomavirus (HPV) is well known as an etiological factor for the development of anogenital carcinomas. The aim of our study was to compare the performance of USFDA approved Hybrid II (HCII) Assay and recently introduced DR. HPV Chip Kit for the detection of HPV DNA in clinical cervical scrapings from 40 patients. HPV DNA testing was performed using the automated HCII Assay system and DR. HPV Chip Kit. Taking cytological results as gold standard, it was found that HCII was more sensitive (36.4%) than DR. HPV Chip Kit (18.2%) although specificity was 100% with the latter method. In addition, both these molecular methods had comparable negative and positive predictive values. It was concluded that both HCII and DR. HPV Chip Kit have comparable specificity. However, sensitivity for detection of HPV in clinical samples with HCII is almost double as compared to DR. HPV Chip Kit.
Rajan
Saini
S
School of Dental Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia. rajan@kb.usm.my
Shen
Tae H
TH
Santhanam
Jacinta
J
Othman
Nor Hayati
NH
Othman
Norodiyah
N
Hock
Tang Thean
TT
D052685:Alphapapillomavirus / Q000302:isolation & purification*; D002584:Cervix Uteri / Q000821:virology; D004279:DNA, Viral; D005260:Female; D006801:Humans; D056656:Lab-On-A-Chip Devices; D046208:Microchip Analytical Procedures / Q000379:methods; D009693:Nucleic Acid Hybridization / Q000379:methods; D030361:Papillomavirus Infections / Q000175:diagnosis*; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity
D004279:DNA, Viral; D011933:Reagent Kits, Diagnostic